Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.

Introduction/background: Primary cutaneous anaplastic large-cell lymphomas (pcALCLs) are a type of cutaneous T-cell lymphoma (CTCL) in which CD30 is uniformly expressed. In mycosis fungoides (MF), another CTCL, CD30 is heterogeneously expressed. In ALCANZA, patients with pcALCLs or CD30-positive MF randomized to brentuximab vedotin (BV) vs. physician's choice of methotrexate or bexarotene had significantly improved outcomes, including higher objective response rates (ORR) lasting ≥4 months (ORR4), as well as longer median progression-free survival (PFS) and time to next treatment (TTNT). In this study, we sought to assess the real-world impact of treatment with BV in second or later lines of therapy for CTCL.
Materials and Methods: This retrospective chart review describes patient characteristics, treatment patterns, clinical outcomes, and healthcare resource use (HRU) in patients with pcALCLs or MF previously treated with ≥1 systemic therapy and subsequently treated with BV (n = 139) or other standard therapy (OST; n = 164).
Results: Most patients in the BV cohort (96.4%) received BV as second-line (2L) systemic therapy. The most common OSTs were methotrexate (11.6%), mogamulizumab (9.1%), and bendamustine (9.1%) monotherapies. For 2L BV and OST, median duration of therapy was 8.4 and 5.2 months, real-world ORR was 82.1% and 66.5%, and real-world ORR4 was 42.5% and 25.0%. Real-world 1- and 2-year PFS, TTNT, and OS were significantly longer (all P < .01) and HRU was lower for BV vs. OST.
Conclusion: These real-world outcomes are consistent with ALCANZA results, demonstrating favorable outcomes with BV vs. OST in patients with CTCL previously treated with ≥1 systemic therapy.
Competing Interests: Disclosure Stefan K. Barta: Consulting Fees: Affimed, Daiichi Sankyo, and Kyowa Kirin; Payment or honoraria for educational events: Acrotech, Kyowa Kirin, and Seagen Inc.; Membership: NCCN T-Cell and Cutaneous Lymphoma Panel; Nicholas Liu: Employee of Seagen Inc.; Stock/Stock Options: Seagen Inc.; Maral DerSarkissian: Employee of Analysis Group, which received research funding from Seagen Inc. to conduct this study; Rose Chang: Employee of Analysis Group, which received research funding from Seagen Inc. to conduct this study; Mingchen Ye: Employee of Analysis Group, which received research funding from Seagen Inc. to conduct this study; Mei Sheng Duh: Employee of Analysis Group, which received research funding from Seagen Inc. to conduct this study; Andy Surinach: Employee of Genesis Research, which received research funding from Seagen Inc. to conduct this study; Michelle Fanale: Employee of Seagen Inc.; Stock/Stock Options: Seagen Inc.; Kristina S. Yu: Employee of Seagen Inc.; Stock/Stock Options: Seagen Inc.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)